Literature DB >> 33562446

Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses.

Zeinab Breijyeh1, Buthaina Jubeh1, Sabino A Bufo2,3, Rafik Karaman1,2, Laura Scrano4.   

Abstract

For thousands of years, Cannabis sativa has been utilized as a medicine and for recreational and spiritual purposes. Phytocannabinoids are a family of compounds that are found in the cannabis plant, which is known for its psychotogenic and euphoric effects; the main psychotropic constituent of cannabis is Δ9-tetrahydrocannabinol (Δ9-THC). The pharmacological effects of cannabinoids are a result of interactions between those compounds and cannabinoid receptors, CB1 and CB2, located in many parts of the human body. Cannabis is used as a therapeutic agent for treating pain and emesis. Some cannabinoids are clinically applied for treating chronic pain, particularly cancer and multiple sclerosis-associated pain, for appetite stimulation and anti-emesis in HIV/AIDS and cancer patients, and for spasticity treatment in multiple sclerosis and epilepsy patients. Medical cannabis varies from recreational cannabis in the chemical content of THC and cannabidiol (CBD), modes of administration, and safety. Despite the therapeutic effects of cannabis, exposure to high concentrations of THC, the main compound that is responsible for most of the intoxicating effects experienced by users, could lead to psychological events and adverse effects that affect almost all body systems, such as neurological (dizziness, drowsiness, seizures, coma, and others), ophthalmological (mydriasis and conjunctival hyperemia), cardiovascular (tachycardia and arterial hypertension), and gastrointestinal (nausea, vomiting, and thirst), mainly associated with recreational use. Cannabis toxicity in children is more concerning and can cause serious adverse effects such as acute neurological symptoms (stupor), lethargy, seizures, and even coma. More countries are legalizing the commercial production and sale of cannabis for medicinal use, and some for recreational use as well. Liberalization of cannabis laws has led to increased incidence of toxicity, hyperemesis syndrome, lung disease cardiovascular disease, reduced fertility, tolerance, and dependence with chronic prolonged use. This review focuses on the potential therapeutic effects of cannabis and cannabinoids, as well as the acute and chronic toxic effects of cannabis use on various body systems.

Entities:  

Keywords:  Cannabis sativa; abuse; cannabinoid receptors; cannabinoids; endocannabinoids; hemp; marijuana; therapeutics; toxicity; Δ-9-tetrahydrocannabinol (THC)

Mesh:

Substances:

Year:  2021        PMID: 33562446      PMCID: PMC7915118          DOI: 10.3390/toxins13020117

Source DB:  PubMed          Journal:  Toxins (Basel)        ISSN: 2072-6651            Impact factor:   4.546


  238 in total

1.  Allosteric modulation of the cannabinoid CB1 receptor.

Authors:  Martin R Price; Gemma L Baillie; Adèle Thomas; Lesley A Stevenson; Morag Easson; Richard Goodwin; Adèle McLean; Lorraine McIntosh; Gillian Goodwin; Glenn Walker; Paul Westwood; Julia Marrs; Fiona Thomson; Phillip Cowley; Arthur Christopoulos; Roger G Pertwee; Ruth A Ross
Journal:  Mol Pharmacol       Date:  2005-08-19       Impact factor: 4.436

2.  Prevalence of gestational exposure to cannabis in a Mediterranean city by meconium analysis.

Authors:  Jaime Lozano; Oscar García-Algar; Emilia Marchei; Oriol Vall; Toni Monleon; Rita Di Giovannandrea; Simona Pichini
Journal:  Acta Paediatr       Date:  2007-10-22       Impact factor: 2.299

3.  Causes and manners of death among users of heroin, methadone, amphetamine, and cannabis in relation to postmortem chemical tests for illegal drugs.

Authors:  Staffan Eksborg; Jovan Rajs
Journal:  Subst Use Misuse       Date:  2008       Impact factor: 2.164

Review 4.  Chronic toxicology of cannabis.

Authors:  Albert Stuart Reece
Journal:  Clin Toxicol (Phila)       Date:  2009-07       Impact factor: 4.467

5.  Marijuana and cocaine impair alveolar macrophage function and cytokine production.

Authors:  G C Baldwin; D P Tashkin; D M Buckley; A N Park; S M Dubinett; M D Roth
Journal:  Am J Respir Crit Care Med       Date:  1997-11       Impact factor: 21.405

6.  Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1).

Authors:  C J Hillard; S Manna; M J Greenberg; R DiCamelli; R A Ross; L A Stevenson; V Murphy; R G Pertwee; W B Campbell
Journal:  J Pharmacol Exp Ther       Date:  1999-06       Impact factor: 4.030

7.  Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS).

Authors:  Mark A Ware; Tongtong Wang; Stan Shapiro; Jean-Paul Collet
Journal:  J Pain       Date:  2015-09-16       Impact factor: 5.820

Review 8.  The evolution and comparative neurobiology of endocannabinoid signalling.

Authors:  Maurice R Elphick
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

Review 9.  Cannabinoids and Pain: New Insights From Old Molecules.

Authors:  Sonja Vučković; Dragana Srebro; Katarina Savić Vujović; Čedomir Vučetić; Milica Prostran
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

10.  Pharmacokinetic, behavioral, and brain activity effects of Δ9-tetrahydrocannabinol in adolescent male and female rats.

Authors:  Christina M Ruiz; Alexa Torrens; Erik Castillo; Christina R Perrone; Jenny Cevallos; Victoria C Inshishian; Eden V Harder; Drew N Justeson; Marilyn A Huestis; Vivek Swarup; Daniele Piomelli; Stephen V Mahler
Journal:  Neuropsychopharmacology       Date:  2020-09-14       Impact factor: 7.853

View more
  11 in total

1.  Anti-inflammatory potential of delta-9-tetrahydrocannabinol in hyperinsulinemia: an experimental study.

Authors:  Zeynep Mine Coskun Yazici; Bilgenur Bilge; Sema Bolkent
Journal:  Mol Biol Rep       Date:  2022-10-14       Impact factor: 2.742

Review 2.  Assessment, pharmacological therapy and rehabilitation management of musculoskeletal pain in children with mucopolysaccharidoses: a scoping review.

Authors:  R Gnasso; B Corrado; I Iommazzo; F Migliore; G Magliulo; B Giardulli; C Ruosi
Journal:  Orphanet J Rare Dis       Date:  2022-07-08       Impact factor: 4.303

Review 3.  The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms.

Authors:  Fatma Haddad; Ghadeer Dokmak; Rafik Karaman
Journal:  Life (Basel)       Date:  2022-05-05

4.  Determining the prevalence of cannabis, tobacco, and vaping device mentions in online communities using natural language processing.

Authors:  Mengke Hu; Ryzen Benson; Annie T Chen; Shu-Hong Zhu; Mike Conway
Journal:  Drug Alcohol Depend       Date:  2021-09-06       Impact factor: 4.492

Review 5.  Small Molecule Compounds of Natural Origin Target Cellular Receptors to Inhibit Cancer Development and Progression.

Authors:  Jinhua Wang; Dangdang Li; Bo Zhao; Juhyok Kim; Guangchao Sui; Jinming Shi
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

Review 6.  Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders.

Authors:  Laura D Carreira; Francisca C Matias; Maria G Campos
Journal:  Biomedicines       Date:  2022-03-29

Review 7.  Poisonous Plants of the Indian Himalaya: An Overview.

Authors:  Abhishek Jamloki; Vijay Laxmi Trivedi; M C Nautiyal; Prabhakar Semwal; Natália Cruz-Martins
Journal:  Metabolites       Date:  2022-06-13

8.  Neurogenetic and Epigenetic Aspects of Cannabinoids.

Authors:  Catherine A Dennen; Kenneth Blum; Abdalla Bowirrat; Jag Khalsa; Panayotis K Thanos; David Baron; Rajendra D Badgaiyan; Ashim Gupta; Eric R Braverman; Mark S Gold
Journal:  Epigenomes       Date:  2022-08-26

Review 9.  Pros and Cons of the Cannabinoid System in Cancer: Focus on Hematological Malignancies.

Authors:  Natasha Irrera; Alessandra Bitto; Emanuela Sant'Antonio; Rita Lauro; Caterina Musolino; Alessandro Allegra
Journal:  Molecules       Date:  2021-06-24       Impact factor: 4.411

10.  Identification and Functional Characterization of Plant Toxins.

Authors:  Zbigniew Adamski; Sabino Aurelio Bufo; Luigi Milella; Laura Scrano
Journal:  Toxins (Basel)       Date:  2021-03-22       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.